him and her CEO Andrew Dadum defended his telehealth company amid a Federal Trade Commission lawsuit over its data-sharing practices.
In a wide-ranging, exclusive interview that aired Tuesday, Dudum argued that the allegations stem from a misunderstanding of how the company is changing health care.
“I can’t say much other than the fact that we’re fundamentally changing the understanding of how traditional systems like health care work and reimagining them in a digital ecosystem,” he told Andrew Ross Sorkin on CNBC’s “Squawk Box.” “I think it’s going to take time for people to understand how to do it the right way, and we’ve been working with the FTC for years to explain it, and I think ultimately they wanted the headlines more than a real agreement here.”
In July, the FTC, Los Angeles County, and the state of Utah filed a lawsuit against Hims & Hers. The company accused it of sharing users’ health information with advertisers like Meta and Snap, charging prescription fees before customers can consult with a health care provider, and making it difficult to cancel subscriptions.
Dudum argued that telehealth providers’ business models are built around increasing access to care.
“We are active disruptors. We take it head on and we will aggressively do it. But always when we believe it is in the best interest of the people and their access,” Dudum said.
Andrew Dudm, co-founder and CEO of Hims & Hers Inc., outside the New York Stock Exchange on August 17, 2026.
new york stock exchange
The CEO of Hims & Hers also mentioned the company’s transition from compounded GLP-1 drugs to branded GLP-1 drugs. When popular obesity and weight-loss drugs ran out of stock in recent years, the company was able to legally sell counterfeit products at discounted prices.
After supplies were restored, Novo Nordisk sued Hims & Hers for patent infringement. In March, the Danish drugmaker dropped the lawsuit and the telemedicine company agreed to sell Novo’s branded drugs on its platform.
The decision came at a time when Novo and its main rival, Eli Lilly, were slashing the price of their GLP-1 drugs for patients to pay out-of-pocket.
“Ultimately, we’re always going to put pressure on the system if we believe that’s what’s best for the consumer. And when we were formulating GLP-1, there was no affordable access to these treatments,” Dudum said. “What’s happened in this ecosystem is that we’ve shown consumers and drug companies that we can bring these medicines to consumers at a price that everyone can afford.”
Dudum said he expects monthly fees for patients who pay cash to eventually drop from about $150 to $200 now to $40 to $50, depending on the form of the drug.
Dudum also believes that artificial intelligence will dramatically change healthcare, and said the company is increasing its investments to eventually become “AI native.” Dudum said Hims & Hers is eliminating third-party AI agents and building everything in-house.
“A core underlying model that is independent of a closed-loop dataset is not very valuable. That’s my honest opinion,” Dudum said. “Closed-loop data within a health system like Hims & Hers, that’s an asset.”
